Loading...

Avanos Medical

DB:8HH
Snowflake Description

Excellent balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8HH
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life worldwide. The last earnings update was 71 days ago. More info.


Add to Portfolio Compare Print
8HH Share Price and Events
7 Day Returns
-4.6%
DB:8HH
-1.2%
DE Medical Equipment
-0.3%
DE Market
1 Year Returns
-23.9%
DB:8HH
7.9%
DE Medical Equipment
-6.7%
DE Market
8HH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Avanos Medical (8HH) -4.6% -2.8% -2.5% -23.9% 21% -
DE Medical Equipment -1.2% 0.8% 3.3% 7.9% 111.6% 256.3%
DE Market -0.3% 2.3% -2% -6.7% 11.3% 12.2%
1 Year Return vs Industry and Market
  • 8HH underperformed the Medical Equipment industry which returned 7.9% over the past year.
  • 8HH underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
8HH
Industry
5yr Volatility vs Market

8HH Value

 Is Avanos Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Avanos Medical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Avanos Medical.

DB:8HH Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:8HH
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.869 (1 + (1- 21%) (16.62%))
0.988
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.99
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.988 * 5.96%)
6.12%

Discounted Cash Flow Calculation for DB:8HH using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Avanos Medical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:8HH DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.12%)
2020 56.00 Analyst x1 52.77
2021 103.00 Analyst x1 91.46
2022 107.00 Analyst x1 89.54
2023 119.00 Analyst x1 93.84
2024 127.93 Est @ 7.51% 95.06
2025 134.74 Est @ 5.32% 94.35
2026 139.86 Est @ 3.79% 92.29
2027 143.67 Est @ 2.72% 89.33
2028 146.51 Est @ 1.98% 85.85
2029 148.63 Est @ 1.45% 82.07
Present value of next 10 years cash flows $866.56
DB:8HH DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $148.63 × (1 + 0.23%) ÷ (6.12% – 0.23%)
$2,528.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,528.83 ÷ (1 + 6.12%)10
$1,396.34
DB:8HH Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $866.56 + $1,396.34
$2,262.90
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,262.90 / 47.50
$47.64
DB:8HH Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:8HH represents 0.92583x of NYSE:AVNS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.92583x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 47.64 x 0.92583
€44.10
Value per share (EUR) From above. €44.10
Current discount Discount to share price of €37.20
= -1 x (€37.20 - €44.10) / €44.10
15.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Avanos Medical is available for.
Intrinsic value
16%
Share price is €37.2 vs Future cash flow value of €44.1
Current Discount Checks
For Avanos Medical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Avanos Medical's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • Avanos Medical's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Avanos Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Avanos Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8HH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.37
NYSE:AVNS Share Price ** NYSE (2019-07-17) in USD $40.18
Germany Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 32.29x
Germany Market PE Ratio Median Figure of 419 Publicly-Listed Companies 20.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Avanos Medical.

DB:8HH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:AVNS Share Price ÷ EPS (both in USD)

= 40.18 ÷ -0.37

-108.72x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avanos Medical is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Avanos Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Avanos Medical's expected growth come at a high price?
Raw Data
DB:8HH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -108.72x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
88.5%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 2.51x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Avanos Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Avanos Medical's assets?
Raw Data
DB:8HH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $27.04
NYSE:AVNS Share Price * NYSE (2019-07-17) in USD $40.18
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.1x
Germany Market PB Ratio Median Figure of 565 Publicly-Listed Companies 1.75x
DB:8HH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:AVNS Share Price ÷ Book Value per Share (both in USD)

= 40.18 ÷ 27.04

1.49x

* Primary Listing of Avanos Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avanos Medical is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Avanos Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Avanos Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

8HH Future Performance

 How is Avanos Medical expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
88.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Avanos Medical expected to grow at an attractive rate?
  • Avanos Medical's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Avanos Medical's earnings growth is expected to exceed the Germany market average.
  • Avanos Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8HH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8HH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 88.5%
DB:8HH Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 6.2%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.5%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8HH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8HH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31 833 2
2021-12-31 788 133 87 5
2020-12-31 742 105 68 6
2019-12-31 695 36 -33 7
DB:8HH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 660 -195 -18
2018-12-31 652 -146 -9
2018-09-30 649 -74 -1
2018-06-30 634 17 -16
2018-03-31 622 134 -29
2017-12-31 612 144 -32
2017-09-30 -171 125 -150
2017-06-30 76 152 -130
2017-03-31 327 183 -112
2016-12-31 566 189 -83
2016-09-30 1,584 167 44
2016-06-30 1,576 136 -435

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Avanos Medical's earnings are expected to grow significantly at over 20% yearly.
  • Avanos Medical's revenue is expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8HH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Avanos Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8HH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 1.85 2.12 1.51 3.00
2020-12-31 1.39 1.64 1.09 4.00
2019-12-31 -0.58 -0.46 -0.69 2.00
DB:8HH Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.37
2018-12-31 -0.18
2018-09-30 -0.03
2018-06-30 -0.34
2018-03-31 -0.61
2017-12-31 -0.69
2017-09-30 -3.21
2017-06-30 -2.79
2017-03-31 -2.41
2016-12-31 -1.79
2016-09-30 0.95
2016-06-30 -9.34

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Avanos Medical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Avanos Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Avanos Medical has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

8HH Past Performance

  How has Avanos Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Avanos Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Avanos Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Avanos Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Avanos Medical's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Avanos Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Avanos Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8HH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 660.10 -17.50 342.70 42.10
2018-12-31 652.30 -8.50 324.70 41.80
2018-09-30 648.70 -1.40 315.80 43.30
2018-06-30 634.10 -15.80 313.00 42.40
2018-03-31 622.30 -28.50 318.30 40.80
2017-12-31 611.60 -32.10 316.70 38.20
2017-09-30 -170.80 -149.60 289.50 35.40
2017-06-30 76.20 -130.30 311.40 36.70
2017-03-31 327.10 -112.40 338.20 37.00
2016-12-31 566.20 -83.30 346.20 38.40
2016-09-30 1,583.70 44.30 421.30 16.90
2016-06-30 1,575.70 -435.30 418.20 16.20
2016-03-31 1,565.00 -433.80 416.10 13.00
2015-12-31 509.00 -101.20 349.70 27.60
2015-09-30 1,612.40 -443.20 443.60 13.00
2015-06-30 1,631.40 19.90 457.70 11.30
2015-03-31 1,655.60 7.40 460.20 14.30
2014-12-31 1,672.10 27.10 441.50 16.60
2014-09-30 1,664.00 69.30 382.60 39.80
2014-06-30 1,675.00 124.60 353.80 40.20
2014-03-31 1,677.40 167.70 337.40 38.70
2013-12-31 1,677.50 154.60 368.40 20.90
2012-12-31 1,684.00 152.60 343.00 33.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Avanos Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Avanos Medical has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Avanos Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Avanos Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Avanos Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

8HH Health

 How is Avanos Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Avanos Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Avanos Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Avanos Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Avanos Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Avanos Medical Company Filings, last reported 3 months ago.

DB:8HH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 1,280.10 247.90 348.30
2018-12-31 1,297.20 247.70 384.50
2018-09-30 1,300.20 247.60 411.80
2018-06-30 1,286.60 247.40 479.60
2018-03-31 1,251.80 542.00 203.10
2017-12-31 1,215.40 580.90 219.70
2017-09-30 1,180.70 580.40 166.10
2017-06-30 1,156.80 579.90 154.80
2017-03-31 1,130.90 579.40 143.10
2016-12-31 1,102.50 579.00 113.70
2016-09-30 1,101.50 589.40 86.70
2016-06-30 1,089.50 624.00 79.20
2016-03-31 1,079.80 578.50 165.10
2015-12-31 1,055.30 578.10 129.50
2015-09-30 1,041.00 585.90 112.50
2015-06-30 1,521.80 585.80 114.30
2015-03-31 1,511.80 635.30 166.20
2014-12-31 1,491.20 626.50 149.00
2014-09-30 2,079.00 10.90 58.40
2014-06-30 2,077.30 10.40 48.50
2014-03-31 2,103.50 9.40 35.80
2013-12-31 2,079.10 11.90 44.10
2012-12-31 2,055.70 75.90 47.90
  • Avanos Medical's level of debt (19.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.4% vs 19.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Avanos Medical has sufficient cash runway for 1.4 years based on current free cash flow.
  • Avanos Medical has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 89.7% each year.
X
Financial health checks
We assess Avanos Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Avanos Medical has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

8HH Dividends

 What is Avanos Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Avanos Medical dividends.
If you bought €2,000 of Avanos Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Avanos Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avanos Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8HH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8HH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Avanos Medical has not reported any payouts.
  • Unable to verify if Avanos Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Avanos Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Avanos Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Avanos Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Avanos Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Avanos Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

8HH Management

 What is the CEO of Avanos Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Woody
COMPENSATION $7,157,269
AGE 53
TENURE AS CEO 2.1 years
CEO Bio

Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Halyard Health, Inc. since June 26, 2017. Mr. Woody served as the Chief Executive Officer and President of Acelity Holdings, Inc. since August 2015 until April 2017. Mr. Woody served as an Interim Chief Executive Officer of LifeCell Corporation since April 12, 2013 until August 2015. He served as the Chief Executive Officer and President of Kinetic Concepts, Inc. and Systagenix Wound Management Limited from September 2013 to August 2015. Mr. Woody served as the Chief Executive Officer of Acelity L.P. Inc. since January 2012 until April 2017 and served as its President. Mr. Woody served as Global President of Vascular Therapies for Covidien plc. He served as Global President of Active Healing Solutions(Tm) at KCI since November 2011. Mr. Woody served in leadership roles at KCI and LifeCell from November 2011 to September 2013, having been promoted to President and Chief Executive Officer of KCI in January 2012. He served as the President of Advanced Wound Management at Smith & Nephew, Inc. Mr. Woody served as Vice President and General Manager of Clinical Therapies Group (Division) of Smith & Nephew Endoscopy, Inc. since March 2004. He served for Alliance Imaging, Inc., Acuson and General Electric Medical Systems (GE Medical Systems) before joining Smith & Nephew in 2003. He has more than 20 years of experience in the healthcare sector. He has been a Director of Chiron Holdings GP, Inc., the general partner of Chiron Guernsey Holdings L.P. Inc., which is the parent of Centaur Guernsey L.P. Inc. since April 3, 2012. He served as a Director at Acelity Holdings, Inc. since August 2015 until April 2017. He served as a Director of Advanced Wound Medical Technology Association (AdvaMed). Mr. Woody served as a Director of Acelity L.P. Inc. since April 3, 2012 until April 2017. He served as a Director of Kinetic Concepts, Inc. He served as a Director of Systagenix Wound Management Ltd. since July 26, 2011. He is chair of the Wound Healing and Tissue Regeneration Sector.

CEO Compensation
  • Joe's compensation has increased whilst company is loss making.
  • Joe's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Avanos Medical management team in years:

1.3
Average Tenure
53
Average Age
  • The average tenure for the Avanos Medical management team is less than 2 years, this suggests a new team.
Management Team

Joe Woody

TITLE
CEO & Director
COMPENSATION
$7M
AGE
53
TENURE
2.1 yrs

John Wesley

TITLE
Senior Vice President of Legal & Government Relations
COMPENSATION
$1M
AGE
60

John Tushar

TITLE
President of Global Franchises
COMPENSATION
$1M
AGE
57
TENURE
1.3 yrs

Arjun Sarker

TITLE
Senior Vice President of International
COMPENSATION
$1M
AGE
53
TENURE
1.3 yrs

Warren MacHan

TITLE
Senior VP of Business Strategy & Interim CFO
AGE
53
TENURE
0.2 yrs

Renato Negro

TITLE
VP, Controller & Chief Accounting Officer

Dave Crawford

TITLE
VP of FP&A and Investor Relations and Treasurer

Rhonda Gibby

TITLE
Senior VP & Chief Human Resources Officer
COMPENSATION
$1M
AGE
51
TENURE
4.8 yrs

Lee Burnes

TITLE
Senior Vice President of Global R&D

Dave Ball

TITLE
Senior Vice President of Global Supply Chain & Procurement
AGE
60
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Avanos Medical board of directors in years:

4.8
Average Tenure
62
Average Age
  • The tenure for the Avanos Medical board of directors is about average.
Board of Directors

Ron Dollens

TITLE
Chairman of the Board
COMPENSATION
$345K
AGE
72
TENURE
1.8 yrs

Joe Woody

TITLE
CEO & Director
COMPENSATION
$7M
AGE
53
TENURE
2.1 yrs

Heidi Fields

TITLE
Independent Director
COMPENSATION
$245K
AGE
64
TENURE
4.8 yrs

Julie Shimer

TITLE
Independent Director
COMPENSATION
$245K
AGE
66
TENURE
4.8 yrs

Gary Blackford

TITLE
Independent Director
COMPENSATION
$245K
AGE
62
TENURE
4.8 yrs

Bill Hawkins

TITLE
Independent Director
COMPENSATION
$245K
AGE
65
TENURE
3.6 yrs

John Byrnes

TITLE
Independent Director
COMPENSATION
$230K
AGE
60
TENURE
4.8 yrs

Patrick O'Leary

TITLE
Independent Director
COMPENSATION
$230K
AGE
61
TENURE
4.8 yrs

Maria Sainz

TITLE
Independent Director
COMPENSATION
$230K
AGE
53
TENURE
4.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Avanos Medical individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Jun 19 Buy Joseph Woody Individual 30. May 19 30. May 19 3,500 €35.88 €125,577
29. Nov 18 Buy Joseph Woody Individual 28. Nov 18 28. Nov 18 3,500 €38.42 €134,474
28. Nov 18 Buy Steven Voskuil Individual 27. Nov 18 27. Nov 18 2,000 €38.73 €77,455
20. Nov 18 Buy John Wesley Individual 19. Nov 18 19. Nov 18 1,000 €41.45 €41,455
X
Management checks
We assess Avanos Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Avanos Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

8HH News

Simply Wall St News

8HH Company Info

Description

Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes. The company also offers Game Read, a product for pain management and rehabilitation of patients recovering from orthopedic surgery or sports-related injuries; GRPro 2.1, a cold and compression therapy system; Med4Elite, a multi-modality therapy unit; ATX Wraps; and various product accessories. In addition, it sells its products under the ON-Q, COOLIEF, MICROCUFF, MIC-KEY, HOMEPUMP, CORTRAK, and GAME READY brand names. The company markets its products directly to hospitals and other healthcare providers, as well as through third-party distribution channels. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Details
Name: Avanos Medical, Inc.
8HH
Exchange: DB
Founded: 2014
$1,701,830,838
47,504,680
Website: http://avanos.com
Address: Avanos Medical, Inc.
5405 Windward Parkway,
Suite 100 South,
Alpharetta,
Georgia, 30004,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE AVNS Common Stock New York Stock Exchange US USD 22. Oct 2014
DB 8HH Common Stock Deutsche Boerse AG DE EUR 22. Oct 2014
Number of employees
Current staff
Staff numbers
4,700
Avanos Medical employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/17 22:39
End of day share price update: 2019/07/17 00:00
Last estimates confirmation: 2019/07/15
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.